<ul><li class="bwlistitemmarginbottom"><i><b>57% of prior treatment null responder patients achieved an SVR
with a 48-week telaprevir-based regimen</b></i></li><li class="bwlistitemmarginbottom"><i><b>90% of prior treatment relapsers and 55% of prior treatment
partial responders achieved an SVR with 24-week or 48-week
telaprevir-based regimens</b></i></li><li class="bwlistitemmarginbottom"><i><b>Results provide further support for the ongoing Phase 3
registration study, REALIZE, in treatment-failure patients</b></i></li></ul>
CAMBRIDGE, Mass., Oct 30, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentations at the Oppenheimer 20 th Annual Healthcare Conference on Wednesday, November 4, 2009 at 2:10 p.m.
<ul><li class="bwlistitemmarginbottom"><i><b>83% SVR achieved with twice-daily regimen of telaprevir dosed
with PEGASYS and ribavirin</b></i></li><li class="bwlistitemmarginbottom"><i><b>Results highlight the use of response-guided therapy in managing
treatment outcomes</b></i></li><li class="bwlistitemmarginbottom"><i><b>Similar safety and tolerability observed between
telaprevir-based regimens dosed either twice daily or three times daily</b></i></li></ul>
CAMBRIDGE, Mass., Nov 10, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that holders of its 4.75% Convertible Senior Subordinated Notes due 2013 have agreed to exchange approximately $109.0 million in aggregate principal amount of those notes and accrued
CAMBRIDGE, Mass., Nov 12, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentation at the Lazard Capital Markets 6th Annual Healthcare Conference on Tuesday, November 17, 2009 at 2:40 p.m. EST.
CAMBRIDGE, Mass., Nov 20, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentations at the Piper Jaffray 21st Annual Health Care Conference on Wednesday, December 2, 2009 at 2:00 p.m.
CAMBRIDGE, Mass., Dec 02, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it intends to offer, subject to market and other conditions, 10,000,000 shares of its common stock in an underwritten public offering under an effective shelf registration
CAMBRIDGE, Mass., Dec 04, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the underwriters of its public offering have exercised in full their option to purchase an additional 1,500,000 shares of common stock at the public offering price of $38.50 per
CAMBRIDGE, Mass., Dec 10, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced the appointment of Nancy J. Wysenski as Executive Vice President and Chief Commercial Officer. Ms. Wysenski has more than 30 years of experience in building commercial operations and